A defined growth medium for Clostridium difficile.

Minimal requirements of amino acids and vitamins were determined in chemically defined medium for five strains of Clostridium difficile. Cysteine, isoleucine, leucine, proline, tryptophan and valine were essential amino acids for growth of C. difficile. Arginine, glycine, histidine, methionine and threonine enhanced growth. Biotin, pantothenate and pyridoxine were essential vitamins. A defined medium containing the minimal requirements of amino acids and vitamins produced a rapid and heavy growth which was comparable to that in modified brain heart infusion, a complex medium. Adenine was able to substitute for glycine and threonine, suggesting that the two amino acids may be utilized as precursors of purine nucleotides. The defined medium developed here will assist physiological and biochemical studies on C. difficile.

[1]  C. Phelps,et al.  Purification and properties of toxins A and B of Clostridium difficile , 1986 .

[2]  J. Bartlett,et al.  Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. , 1978, The New England journal of medicine.

[3]  S. Nakamura,et al.  Antimicrobial Susceptibility of Clostridium difficile from Different Sources , 1982, Microbiology and immunology.

[4]  N. Sullivan,et al.  Enzyme-linked immunosorbent assay for Clostridium difficile toxin A , 1983, Journal of clinical microbiology.

[5]  S. Borriello,et al.  Effect of Nutrition on the Expression of Known and Putative Virulence Factors of Clostridium difficile , 1991 .

[6]  J. Bartlett,et al.  Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. , 1978, Gastroenterology.

[7]  S. Borriello,et al.  Antibiotic and pseudomembranous colitis. , 1981, The Journal of antimicrobial chemotherapy.

[8]  A. Sonenshein.  Introduction to Metabolic Pathways , 1993 .

[9]  A. Price,et al.  CLOSTRIDIUM DIFFICILE AND THE ÆTIOLOGY OF PSEUDOMEMBRANOUS COLITIS , 1978, The Lancet.

[10]  E. Johnson,et al.  Development of improved defined media for Clostridium botulinum serotypes A, B, and E , 1988, Applied and environmental microbiology.

[11]  J M Ketley,et al.  Growth of Clostridium difficile and production of toxins A and B in complex and defined media. , 1986, Journal of medical microbiology.

[12]  M. A. Logan,et al.  The growth requirements of Clostridium perfringens (welchii) BP6K. , 1948, The Journal of biological chemistry.

[13]  S. Borriello,et al.  H y d ro I yt i c enzyme p rod u c t i o n by COstridium dificile and its relationship to toxin production and virulence in the hamster model , 1990 .

[14]  S. Borriello,et al.  Detection of fimbriae amongst strains of Clostridium difficile , 1988 .

[15]  N. Sullivan,et al.  Purification and characterization of toxins A and B of Clostridium difficile , 1982, Infection and immunity.

[16]  G. Bonde,et al.  The nutritional requirements of Clostridium perfringens. , 1957, Journal of general microbiology.

[17]  Y. Banno,et al.  Biochemical characterization and biologic actions of two toxins (D-1 and D-2) from Clostridium difficile. , 1984, Reviews of infectious diseases.

[18]  S. Nakamura,et al.  Isolation of Clostridium difficile from the Feces and the Antibody in Sera of Young and Elderly Adults , 1981, Microbiology and immunology.

[19]  S. Nakamura,et al.  Germinability and Heat Resistance of Spores of Clostridium difficile Strains , 1985, Microbiology and immunology.

[20]  T. Honda,et al.  STIMULATION OF ENTEROTOXIN PRODUCTION OF CLOSTRIDIUM DIFFICILE BY ANTIBIOTICS , 1983, The Lancet.

[21]  T. Wilkins,et al.  Clostridium difficile: its disease and toxins , 1988, Clinical Microbiology Reviews.

[22]  E. Goldstein,et al.  Aetiology of antimicrobial-agent-associated colitis. , 1978, Lancet.